Jianying Zhou
Zhejiang International Studies University(CN)University of Science and Technology of China(CN)Houston Methodist(US)Fujian Medical University(CN)Johns Hopkins University(US)Liaoning Normal University(CN)Henan University(CN)Jilin University(CN)Chinese Academy of Medical Sciences & Peking Union Medical College(CN)Peking University(CN)Fudan University(CN)Sir Run Run Shaw Hospital(CN)Wuhan University(CN)Xinyang College of Agriculture and Forestry(CN)Central China Normal University(CN)National Cancer Center(US)National Clinical Research Center for Digestive Diseases(CN)Methodist Hospital(US)Zhejiang Cancer Hospital(CN)Guangzhou Women and Children Medical Center(CN)Methodist Hospital(US)Zhejiang Hospital(CN)Beijing Municipal Ecological and Environmental Monitoring Center(CN)Peking University People's Hospital(CN)First Hospital of Jilin University(CN)Beijing Aerospace General Hospital(CN)The First People’s Hospital of Lianyungang(CN)Second Affiliated Hospital of Fujian Medical University(CN)Zhejiang Center for Disease Control and Prevention(CN)Jilin Medical University(CN)Institute of High Energy Physics(CN)First Affiliated Hospital of Henan University of Traditional Chinese Medicine(CN)Institute of Bioinformatics(IN)Sanya University(CN)Ministry of Agriculture and Rural Affairs(CN)University of Chinese Academy of Sciences(CN)First Affiliated Hospital Zhejiang University(CN)Anyang Hospital of Traditional Chinese Medicine(CN)China Agricultural University(CN)Weifang University(CN)Zhejiang University(CN)Guangzhou Medical University(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Particle physics theoretical and experimental studies, Quantum Chromodynamics and Particle Interactions, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment
Most-Cited Works
- → Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial(2019)2,107 cited
- → Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study(2020)1,586 cited
- → Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer(2016)1,090 cited
- → Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial(2020)492 cited
- → [Management of COVID-19: the Zhejiang experience].(2020)474 cited
- → Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial